Liver and Bile
J Hepatol. 2023;79(5):1150–8
Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial
Background and aims: Acute hepatic porphyria (AHP) is caused by defects in hepatic heme biosynthesis, leading to disabling acute neurovisceral attacks and chronic symptoms. In ENVISION, givosiran treatment for 6 months reduced attacks and other disease manifestations compared with placebo. Herein, the authors report data from the 36-month final analysis of ENVISION.
Methods: 94 patients with AHP (age ≥ 12 years) and recurrent attacks were randomized 1:1 to monthly double-blind subcutaneous givosiran 2.5 mg/kg (n = 48) or placebo (n = 46) for 6 months. In the open-label extension (OLE) period, 93 patients received givosiran 2.5 mg or 1.25 mg/kg for 6 months or more before transitioning to 2.5 mg/kg. End points were exploratory unless otherwise noted.
Results: During givosiran treatment, the median annualized attack rate (AAR) was 0.4. Through month 36, annualized days of hemin use remained low in the continuous givosiran group (median, 0.0 to 0.4) and decreased in the placebo crossover group (16.2 to 0.4). At the end of OLE, in the continuous givosiran and placebo crossover groups, 86% and 92%, respectively, had 0 attacks. AAR was lower than historical AAR in 98% and 100%, respectively (post-hoc analysis), and there were 0 days of hemin use in 88% and 90%, respectively. The 12-item short-form health survey physical and mental component summary scores increased by 8.6 and 8.1, respectively (continuous givosiran) and 9.4 and 3.2, respectively (placebo crossover). EQ-5D health-related questionnaire scores increased by 18.9 (continuous givosiran) and 9.9 (placebo crossover). Lower urinary delta-aminolevulinic acid and porphobilinogen levels were sustained. Safety findings demonstrated a continued positive risk/benefit profile for givosiran.
Conclusions: Long-term monthly givosiran treatment provides sustained and continued improvement in clinical manifestations of acute hepatic porphyria.